125 related articles for article (PubMed ID: 2001555)
1. The relationship of ABH(O) blood group antigen expression in intraepithelial dysplastic lesions to clinicopathologic properties of associated transitional cell carcinoma of the bladder.
Yamada T; Fukui I; Kobayashi T; Sekine H; Yokogawa M; Yamada T; Oshima H
Cancer; 1991 Mar; 67(6):1661-6. PubMed ID: 2001555
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of the A, B and H isoantigens in single transitional carcinoma cells.
Borgström E; Wahren B
J Urol; 1985 Jul; 134(1):199-202. PubMed ID: 3892047
[TBL] [Abstract][Full Text] [Related]
3. [Isoantigens ABH in bladder tumors as an indicator of malignant potential. III. Detection by PAP method and a classification of staining pattern].
Nasu Y; Kumon H; Matsumura Y; Ohmori H
Nihon Hinyokika Gakkai Zasshi; 1984 May; 75(5):739-43. PubMed ID: 6208400
[No Abstract] [Full Text] [Related]
4. Correlation of ABH antigenicity and urine cytology results in transitional cell carcinoma of bladder.
Gorelick JI; Oyasu R; Golmon ME; Grayhack JT
Urology; 1984 Sep; 24(3):287-90. PubMed ID: 6474644
[TBL] [Abstract][Full Text] [Related]
5. Blood group ABH-related antigens in normal and malignant bladder urothelium: possible structural basis for the deletion of type-2 chain ABH antigens in invasive carcinomas.
Orntoft TF; Wolf H; Clausen H; Dabelsteen E; Hakomori S
Int J Cancer; 1989 May; 43(5):774-80. PubMed ID: 2497072
[TBL] [Abstract][Full Text] [Related]
6. Investigation of ABH antigenicity of random mucosal biopsies and transitional cell carcinoma of the urinary bladder.
Jakse G; Hofstädter F
Eur Urol; 1983; 9(2):97-101. PubMed ID: 6852091
[TBL] [Abstract][Full Text] [Related]
7. Expression of blood-group-related antigens in carcinoma in situ of the urinary bladder.
Coon JS; McCall A; Miller AW; Farrow GM; Weinstein RS
Cancer; 1985 Aug; 56(4):797-804. PubMed ID: 4016671
[TBL] [Abstract][Full Text] [Related]
8. A modified immunoperoxidase method for the detection of ABH tissue isoantigens in patients with bladder carcinoma.
Stul MS; Logghe GN; Bergmans GB; Vanvuchelen JK
Exp Pathol; 1985; 27(2):119-22. PubMed ID: 3888650
[TBL] [Abstract][Full Text] [Related]
9. Behavior of epithelial differentiation antigens (carcinoembryonic antigen, epithelial membrane antigen, keratin and cytokeratin) in transitional cell carcinomas of the bladder.
Sánchez-Fernández de Sevilla MC; Morell-Quadreny L; Gil-Salom M; Pérez-Bacete M; Fenollosa-Entrena B; Llombart-Bosch A
Urol Int; 1992; 48(1):14-9. PubMed ID: 1376008
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies to detect A, B and H blood group isoantigens in superficial transitional cell carcinoma of the bladder: a means of predicting invasive recurrences.
Stephenson TJ; Williams JL; Gelsthorpe K
Br J Urol; 1985 Apr; 57(2):148-53. PubMed ID: 3886066
[TBL] [Abstract][Full Text] [Related]
11. Changing expression of ABH blood group and cryptic T-antigens of noninvasive and superficially invasive papillary transitional cell carcinoma of the bladder from initial occurrence to malignant progression.
Yamada T; Fukui I; Yokokawa M; Oshima H
Cancer; 1988 Feb; 61(4):721-6. PubMed ID: 3338034
[TBL] [Abstract][Full Text] [Related]
12. ABO (H) blood group antigens and carcinoembryonic antigens as indicators of malignant potential in patients with transitional cell carcinoma of the bladder.
Nakatsu H; Kobayashi I; Onishi Y; Igawa M; Ito H; Tahara E; Nihira H
J Urol; 1984 Feb; 131(2):252-7. PubMed ID: 6366250
[TBL] [Abstract][Full Text] [Related]
13. A, B, H antigen expression in transitional cell carcinomas of the urinary bladder.
Juhl BR; Hartzen SH; Hainau B
Cancer; 1986 May; 57(9):1768-75. PubMed ID: 2420436
[TBL] [Abstract][Full Text] [Related]
14. The prediction of invasive potential in superficial transitional cell carcinoma of the bladder.
Finan PJ; Anderson JR; Doyle PT; Lennox ES; Bleehen NM
Br J Urol; 1982 Dec; 54(6):720-5. PubMed ID: 6758916
[TBL] [Abstract][Full Text] [Related]
15. [Isoantigens ABH in bladder tumors as an indicator of malignant potential. II. Results of a long-term follow-up and technical problems].
Kumon H; Nasu Y; Matsumura Y; Ohmori H
Nihon Hinyokika Gakkai Zasshi; 1984 May; 75(5):731-8. PubMed ID: 6492527
[No Abstract] [Full Text] [Related]
16. [Relations of clinicopathological findings to expression of ABH blood group and Thomsen-Friedenrich antigens in initially superficial papillary transitional cell carcinomas of the bladder developing subsequent malignant progression].
Yamada T; Fukui I; Yokogawa M; Oshima H
Nihon Hinyokika Gakkai Zasshi; 1988 Jun; 79(6):1049-53. PubMed ID: 3184579
[No Abstract] [Full Text] [Related]
17. A monoclonal antibody (BL2-10D1) reacting with a bladder-cancer-associated antigen.
Longin A; Hijazi A; Berger-Dutrieux N; Escourrou G; Bouvier R; Richer G; Mironneau I; Fontanière B; Devonec M; Laurent JC
Int J Cancer; 1989 Feb; 43(2):183-9. PubMed ID: 2645218
[TBL] [Abstract][Full Text] [Related]
18. The cell surface antigen A, B or O(H) as an indicator of malignant potential in stage A bladder carcinoma: preliminary report.
Bergman S; Javadpour N
J Urol; 1978 Jan; 119(1):49-51. PubMed ID: 621814
[TBL] [Abstract][Full Text] [Related]
19. A, B, H antigens in transitional cell tumors of the urinary bladder: correlation with the clinical course.
Limas C; Lange P; Fraley EE; Vessella RL
Cancer; 1979 Dec; 44(6):2099-107. PubMed ID: 509389
[TBL] [Abstract][Full Text] [Related]
20. [The study of the ABH isoantigen of bladder tumors].
Fukatsu H; Nonomura H; Miyagawa Y; Waki M; Hatano Y; Hiraiwa S; Muramatsu T; Takamura T; Yamada Y; Nishikawa E
Hinyokika Kiyo; 1987 Jun; 33(6):857-63. PubMed ID: 3314420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
